Research testing for ADRB2 now available at Ambry Genetics

IRVINE, CA (November 12, 2004) – AMBRY GENETICS, a leading genetic testing company, announced it has added a new research test to its product line. Ambry Genetics is offering ADRB2 sequencing, including the exon, 5' UTR and 5' leader cistron, to aid in research studies. ADRB2 emerges to be a significant disease modifier in asthma and bronchial disorders.

Asthma is a chronic inflammatory disorder affecting the airways. The etiology of the disease includes environmental and genetic factors. The beta(2) adrenergic receptor (ADRB2), a member of the G-protein coupled receptor family, is the most common adrenergic receptor in the lung and is important for cAMP regulation in the airway. It is a target for the treatment of bronchospasm.

Associations between ADRB2 polymorphism status and phenotypes of asthma activity, asthma drug response, nocturnal asthma and bronchial hyper responsiveness have been reported. Research studies have shown that the polymorphism status can alter receptor function and expression, and ADRB2 shows potential to be an important disease modifier. Yet, further extensive population studies are needed to clearly discern genotype-phenotype correlations. Ambry Genetics has several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes.

Ambry Genetics Launches New Website

www.ambrygen.com Offers Expanded Content for Medical Professionals and Customers

IRVINE, CA (November 22, 2004) – AMBRY GENETICS, a leading genetic testing company, announced that it has launched a redesigned and enhanced corporate Web site www.ambrygen-.com, which offers comprehensive information on the Company's innovative tests for cystic fibrosis, pancreatitis, colon cancer (HNPCC) and research testing offerings.

"Because the importance of accurate genetic assessment cannot be underestimated, we have a unique opportunity to educate and inform site visitors while making it easy for healthcare professionals to conduct business with us," said Charles L. M. Dunlop, CEO of Ambry Genetics. "Our new site showcases the unprecedented knowledge and experience we have gained over the years with thousands of known disease-causing mutations and previously unreported mutations. It also reflects our commitment to building successful relationships with all our customers, potential partners and prospective employees."

Ambrygen.com features extensive audience-specific information organized in expanded Test Directory, Ordering, Improved Billing and Resources sections. The site design has been optimized for faster loading and efficient navigation and features informative Corporate and Current News sections.

Besides being a valuable resource for healthcare professionals, the Ambry Genetics website can assist a patient in their research, so they can ask the right questions and participate actively in decision-making with caregivers. Comprehensive genetic testing provides a solid basis for proper therapy and for the practice of preventative medicine.

AMBRY GENETICS

Ambry Genetics is a worldwide leader in specialized genetic testing. The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene's entire coding region plus surrounding critical introns. Capable of identifying more than 99% of the known disease-causing mutations of the CFTR gene, the company's reputable Cystic Fibrosis test has an unrivaled detection rate of over 96% across all ethnic groups. The Company also created the world's first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics most recent development detects mutations of the most significant genes (MLH1, MSH2) causing hereditary colon cancer, significantly optimizing patient management and risk assessment. Headquartered in Irvine, California, the Company's advancements are providing precise, cost effective methods to aid in disease definition and early, more accurate diagnosis.

Several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes. Website: www.ambrygen.com

Michelle B. Hamilton
VP Marketing
Ambry Genetics
100 Technology Drive
Irvine, CA 92618
www.ambrygen.com

The "New Products" page is designed to offer you news and information from businesses serving the genetics community. We welcome your submissions. All submissions are subject to review by the Editor. For more information, contact Al Lucchesi, National Accounts Manager, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106; phone 215-521-8409; fax 215-521-8411; email alucches@lww.com.